Alembic Pharma to raise up to Rs 300 crore via issuance of NDCs

Published On 2019-06-13 04:30 GMT   |   Update On 2019-06-13 04:30 GMT

Alembic Pharma has approved the issue of unsecured listed rated redeemable non-convertible debentures (NCDs) of up to Rs 300 crore on a private placement basis. However, it did not specify the reason for raising funds but said it will issue NCDs in one or more tranches.


New Delhi: Drug firm Alembic Pharmaceuticals Wednesday said its board has approved raising of up to Rs 300 crore through issuance of non-convertible debentures (NCDs) on a private placement basis.


The company, which did not specify the reasons for raising funds, said it will issue NCDs in one or more tranches.


"The board of directors of Alembic Pharmaceuticals Ltd....has approved the issue of unsecured listed rated redeemable non-convertible debentures (NCDs) of up to Rs 300 crore on a private placement basis," the company said in a regulatory filing.


Also Read: Alembic Pharma gets USFDA nod for Carbidopa and Levodopa extended-release tablets for Parkinson’s treatment


Prior to this, the company had raised Rs 150 crore through the allotment of non-convertible debentures (NCDs) on private placement basis. Medical Dialogues had earlier reported that these NCDs carried a coupon rate of 8.37 per cent per annum and were proposed to be listed on NSE.


Also Read: Alembic Pharma raises Rs 150 crore via NCDs







Alembic Pharma is headquartered in Vadodara city of Gujarat and is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates.




Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News